The fact that NKTR-214 is a reformulation of IL-2—rather than some drug with a novel or unknown MoA—is pertinent in this discourse. I highly doubt that BMY/NKTR would go to phase-3 based on small-n single-arm arm data if the MoA were not well characterized.
News 
Market Data 
Discover 
